Table 3.
UACR* at 3, 6, 9, and 12 months of treatment
| Time-point | N | Total | N | Cilnidipine | N | Amlodipine | |
|---|---|---|---|---|---|---|---|
| Baseline log transformed 3 months log transformed 6 months log transformed 9 months log transformed 12 months log transformed |
365 345 330 319 330 |
99.67±107.82 4.32±0.69 80.32±97.93 3.94±0.91 80.09±93.86 3.94±0.91 91.33±96.22 4.10±0.90 98.38±115.07 4.12±0.95 |
179 170 162 158 163 |
111.50±138.97 4.37±0.76 85.05±114.06 3.96±0.93 81.71±95.95 3.94±0.93 97.67±101.55 4.15±0.93 107.93±130.23 4.16±1.02 |
186 175 168 161 167 |
88.29±63.45 4.28±0.62 75.73±79.25 3.92±0.88 78.53±92.06 3.94±0.89 85.10±90.57 4.05±0.87 89.07±97.55 4.08±0.88 |
|
| The change in the natural logarithm from baseline | |||||||
| Time-point | N | Total | N | Cilnidipine | N | Amlodipine | p-value ** |
| 3 months 6 months 9 months 12 months |
345 330 319 330 |
-0.38±0.74 -0.38±0.78 -0.23±0.74 -0.21±0.78 |
170 162 158 163 |
-0.40±0.76 -0.42±0.83 -0.21±0.77 -0.21±0.86 |
175 168 161 167 |
-0.35±0.72 -0.34±0.73 -0.24±0.70 -0.21±0.69 |
0.586 0.441 0.764 0.96 |
* UACR: Urinary albumin to creatinine ratio. Data are expressed as mg/g. ** Analysis of covariance considering stratification factors of randomization was used for examining the difference means of the change in the log-transformed UACR at each time point. Multiplicity was not considered.